India plays a vital role in the global pharmaceutical and vaccine industries. Often referred to as the "Pharmacy of the World," India has emerged as the largest provider of generic medicines globally, contributing 20% to the global supply volume and approximately 60% to the worldwide vaccine market. These impressive numbers underline India's significance as a reliable and affordable supplier of high-quality pharmaceuticals to various countries, particularly in low- and middle-income nations.
In terms of production, India ranks third globally by volume, and while its value is not as high, it stands as the 14th largest in value, highlighting its focus on large-scale, cost-effective production. The Indian pharmaceutical industry is segmented into various categories, including Over-the-Counter (OTC) medicines, generics, Active Pharmaceutical Ingredients (APIs), vaccines, biosimilars, and Custom Research Manufacturing (CRM). This vast range of products has helped India carve a unique space in the international market.
India’s dominance is particularly pronounced in vaccines, with a stronghold in the production of DPT, BCG, and measles vaccines. The country also boasts the highest number of U.S. FDA-approved plants outside the USA, further cementing its leadership in the pharmaceutical sector. The success of the industry lies in its unique selling proposition (USP) of providing affordable yet high-quality medicines, which has made Indian pharmaceuticals highly sought after globally.
In FY23, the Indian pharmaceutical industry's total annual turnover reached $49.78 billion, compared to $41.68 billion in FY22. Among its most significant achievements are providing affordable HIV drugs globally and being a major supplier of low-cost vaccines. This strong foundation places India at the forefront of global pharmaceutical exports, with a major portion coming from drug formulations and biologics, contributing to about 75% of the total exports.
India’s Export Trends in Pharmaceuticals
India's pharmaceutical exports have seen consistent growth over the years, accounting for 5.71% of the global pharmaceuticals and drugs market. In FY24 (up until February 2024), pharmaceutical exports from India stood at $25.02 billion, nearly matching the previous year's total of $25.4 billion. The country's robust performance in exports has been sustained despite global supply chain disruptions, such as those caused by the COVID-19 pandemic, demonstrating India's resilience in maintaining a stable supply of critical medicines.
Between 2020 and 2021, India's pharmaceutical exports grew by an impressive 18% YoY, reaching $24.44 billion. This surge continued into FY23, during which India exported $24.59 billion worth of pharmaceutical products. Even amid supply chain challenges, lockdowns, and production slowdowns, India's pharmaceutical industry managed to maintain its foothold in international markets. This resilience is a key factor in India's growing stature as a reliable pharmaceutical supplier.
India's top five export destinations in FY23 were the USA, Belgium, South Africa, the UK, and Brazil. The United States alone accounted for 29.72% of Indian pharmaceutical exports, valued at $7.54 billion, underscoring the country's reliance on Indian generics and biologics. Belgium and South Africa followed, with exports valued at $714.92 million and $657 million, respectively. This trend is expected to continue, with growing market opportunities and rising demand, particularly in highly regulated markets like the U.S. Over 55% of Indian pharmaceutical exports are directed to these regulated markets, further enhancing India's global reach.
The Role of Vaccines in India's Pharmaceutical Export Industry
India is the largest vaccine exporter in the world, accounting for 65-70% of the World Health Organization’s (WHO) vaccine requirements. With the pandemic highlighting the critical importance of vaccine production and distribution, India played a pivotal role by supplying vaccines globally even in times of crisis. This placed India firmly on the world map as a reliable supplier of affordable vaccines.
India’s leadership in the global vaccine market has been critical in ensuring vaccine equity,
for low-income countries. India's affordable vaccines have played a key role in combating preventable diseases across the globe. This leadership extends to more complex biologics as well, which are becoming increasingly critical in modern healthcare.India’s success in vaccine production is reinforced by the country’s stringent adherence to quality control standards. As of 2023, India had 6,316 U.S. FDA-approved market authorizations for formulations, more than any other country. This is a testament to the country's stringent quality control measures and its capability to meet global regulatory standards.
India’s Pharmaceutical Exports to Africa
Africa has become one of the most significant destinations for Indian pharmaceutical exports, with India playing a critical role in meeting the continent’s healthcare needs. In FY23, Indian pharmaceutical exports to Africa stood at $3.04 billion, a significant portion of India’s total exports. Africa accounts for nearly 17% of India’s total pharmaceutical exports, highlighting the importance of the African market in India’s global strategy.
The demand for Indian generics and affordable medicines is especially strong in countries like South Africa, Nigeria, Kenya, and Ghana, where healthcare systems face challenges related to affordability and access. Indian pharmaceuticals, known for their cost-effectiveness, have proven to be a lifeline for many African nations, offering treatments for infectious diseases such as malaria, tuberculosis, and HIV/AIDS at significantly lower costs than those provided by other global manufacturers.
Indian companies are increasingly collaborating with African governments and local pharmaceutical companies to address the continent’s unique healthcare challenges. These collaborations aim to ensure a steady supply of essential medicines while also supporting local capacity-building initiatives. India’s pharmaceutical exports to Africa are not just about generics; they also include vaccines, which have played a pivotal role in immunization programs across the continent. The Serum Institute of India, for example, is a key supplier of vaccines to Africa, providing affordable vaccines for diseases such as polio, measles, and pneumonia.
India’s growing influence in the African market is further supported by strong diplomatic and trade relations. The Indian government, through its Africa-focused initiatives, has helped facilitate the export of pharmaceuticals and other medical supplies. This includes extending lines of credit to African countries for healthcare projects, which often involve the procurement of medicines and medical equipment from Indian companies. Additionally, initiatives such as the Pan-African e-Network Project, which connects African nations to India’s healthcare expertise through telemedicine, underscore the depth of India’s commitment to improving healthcare outcomes in Africa.
Export Destinations and Market Dynamics
India exports pharmaceutical products to various regions, including North America, Africa, the European Union (EU), ASEAN, Latin America & Caribbean (LAC), the Middle East, Asia, and CIS. Nearly two-thirds of these exports go to North America, Europe, and Africa. The U.S. remains India’s largest export market for pharmaceuticals, accounting for 31% of total exports. The UK and the Netherlands, each representing about 3% of the total, have also become significant markets for Indian pharmaceutical products.
In FY24, the inclusion of new markets like Montenegro, South Sudan, Chad, Comoros, Brunei, Latvia, Ireland, Sweden, Haiti, and Ethiopia has further diversified India’s export portfolio. This expansion into previously untapped regions reflects India’s growing global footprint and the increasing recognition of its pharmaceutical products.
The Indian pharmaceutical industry’s reputation for reliability and affordability, coupled with its strong regulatory compliance, has driven its consistent performance in these export markets. For example, the U.S. FDA granted 410 Type II DMFs (Drug Master Files) to Indian pharmaceutical companies in the first half of 2023 alone, a 17% increase from the previous year. The rising number of U.S. FDA inspections of Indian facilities post-pandemic will further boost India’s exports to the U.S. in the coming years.
Government Initiatives Supporting the Pharmaceutical Industry
The Indian government has launched multiple initiatives to strengthen the domestic pharmaceutical industry and enhance its global competitiveness. The Strengthening of Pharmaceutical Industry (SPI) scheme, with a financial outlay of ₹500 crore ($64.5 million), aims to improve infrastructure facilities across the country. This scheme is expected to bolster the industry by improving production capabilities, particularly for small and medium-sized enterprises (SMEs).
The Production Linked Incentive (PLI) scheme is another major initiative, designed to promote domestic manufacturing of critical pharmaceutical ingredients. With an investment of ₹6,940 crore ($834 million) until 2029-30, this scheme has already attracted significant investment. As of September 2023, 48 projects have been approved under the PLI scheme, generating over 9,600 jobs and attracting investments worth ₹3,938 crore ($473 million). This initiative aims to reduce India’s dependency on imports for APIs and improve self-reliance in pharmaceutical production.
In addition, the Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS) aims to help small and medium-sized enterprises (SMEs) meet international standards, particularly WHO-GMP norms. This initiative will allow SMEs to compete in global markets and enhance their production capabilities.
Future Growth Prospects
Experts predict that India’s pharmaceutical industry could surpass $130 billion by 2030, driven by expanding market opportunities and the rising demand for affordable medicines globally. The sector is already producing more than 60,000 generic drugs across 60 therapeutic categories, demonstrating its capability to meet the growing needs of global healthcare systems.
India’s pharmaceutical exports are expected to maintain a consistent growth trajectory, averaging $2-3 billion per month. This steady performance in international trade, supported by favorable government policies and the continued expansion into new markets, underscores the vital role India will continue to play in the global pharmaceutical landscape.
As the industry evolves, with greater emphasis on biologics, biosimilars, and custom research manufacturing, India is poised to remain a key player in the global pharmaceutical market for years to come. By focusing on innovation, affordability, and quality, India’s pharmaceutical sector is well-positioned to meet the challenges and opportunities of the future, solidifying its reputation.
Comments